Kacper A Walentynowicz, PhD

📢 Today we celebrate International Day of LGBTQIA+ People In STEM!

📷 A drop of rainbow” (Lara Barrio): 🔴🟢🔵 With just three fluorescent markers it's possible to generate 7 colour combinations that allow researchers to track multiple cell populations in #Drosophila.

#LGBTQSTEMDay #PrideInSTEM

🧪

Thank you for the recognition! ☺️ @mskcancercenter.bsky.social @mskeducation.bsky.social

We're back with another exciting session — this time, spotlight on microglial cells!
And wait until you see our star-studded lineup of speakers!
Don't miss it — join us and stay at the forefront of the latest research!

@soyonhonglab.bsky.social

#WGC #GLIA

Life Sciences Technology Innovation Fellows Program - Entrepreneurship at Cornell Read more about BioEntrepreneurship

I'm excited to share that I've been selected to join the Life Sciences Technology Innovation Fellows Program at Cornell SC Johnson College of Business. The future is bright! @scjohnsoncollege.bsky.social #entrepreneurship #science

Single-cell RNA sequencing of immune cells for over 1,000 people age 18-97 years. A clock of our immune system aging. Tells us about an individual's response to infection, vaccination, Long Covid. Towards an immunome.
www.nature.com/articles/s43...

Going to the 2025 #MIT #European #Career #Fair this weekend, & wondering how to #fund your future #research?

Visit the 🇪🇺 European Union's stand to find out all about European Research Council's #grants!

Info 👉 europa.eu/!M4MWm8

#EURAXESS #Europe #Science #Grant #Funding @mitofficial.bsky.social

Functional differences between rodent and human PD-1 linked to evolutionary divergence A highly conserved motif in human PD-1 but absent in rodent PD-1 is linked to differential inhibitory activity.

Functional differences between rodent and human PD-1 linked to evolutionary divergence | Science Immunology www.science.org/doi/10.1126/...

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial - Nature Medicine In a first-in-human phase 1 trial, HER2-specific CAR macrophages were feasible to manufacture and well tolerated, with no dose-limiting toxicities in patients with HER2-overexpressing solid tumors.

Carisma Therapeutics reports Phase 1 results of CT-0508, an anti-HER2 CAR #macrophage that has already been deprioritized, in advanced/metastatic #HER2 overexpressing solid tumors (14 pts). CAR-M therapy is feasible and well-tolerated.

@natmedicine.bsky.social

www.nature.com/articles/s41...

Miltenyi Biotec on LinkedIn: The application period for the 2024 MACS® Imaging Grant program has… The application period for the 2024 MACS® Imaging Grant program has concluded.  We are honored that so many researchers shared their brilliant ideas with us on…

Happy to announce my collaboration with Miltenyi Biotec, using their spatial platform to study cellular crosstalk and vulnerabilities for CAR-macrophage treatment in GBM!